DENTSPLY SIRONA Inc. (NASDAQ:XRAY) has a beta of 1.06, a 12-month trailing P/E ratio of 130.90, and a growth ratio of 13.44. The stock’s Relative Strength Index (RSI) is 75.09, with weekly volatility at 2.72% and ATR at 1.78. The XRAY stock’s 52-week price range has touched low of $31.58 and a $60.87 high. Its shares traded higher over the last trading session, gaining 5.30% on 06/04/20. The shares fell to a low of $47.09 before closing at $50.59. Intraday shares traded counted 0.78 million, which was 73.87% higher than its 30-day average trading volume of 2.98M. XRAY’s previous close was $48.04 while the outstanding shares total 220.90M.
Investors have identified the Medical Instruments & Supplies company DENTSPLY SIRONA Inc. as an interesting stock but before investments are made there, an in-depth look at its trading activities will have to be conducted. The share is trading with a market value of around $10.63 billion, the company now has both obstacles and catalysts that affect them and they came from their mode of operations. With the company affected by events currently, it is a perfect time to analyze the numbers behind the firm in order to come up with a rather realistic picture of what this stock is.
DENTSPLY SIRONA Inc. (XRAY) Fundamentals that are to be considered.
When analyzing a stock, the first fundamental thing to take into account is the balance sheet. How healthy the balance sheet of a company is will determine if the company will be able to carry out all its financial and non-financial obligations and also keep the faith of its investors. In terms of their assets, the company currently has 1805200000 million total, with 891500000 million as their total liabilities.
XRAY were able to record -36.3 million as free cash flow during the third quarter of the year, this saw their quarterly net cash flow reduce by -169.0 million. In cash movements, the company had a total of -10.7 million as operating cash flow.
Potential earnings growth for DENTSPLY SIRONA Inc. (XRAY)
In order to determine the future investment potential for this stock, we will have to analyze key trends that affect it. During the third quarter of the year, DENTSPLY SIRONA Inc. recorded a total of 874.3 million in revenue. This figure implies that they witnessed a quarterly year/year change in their earnings with -8.22% coming in sequential stages and their sales for the third quarter reducing by -27.13%.
What matters though is how it ends. When the core data for the company is broken down, then the stock sounds interesting. The company spent 406.5 million trying to sell their products during the last quarter, with the result yielding a gross income of 467.8 million. This allows shareholders to hold on to 220.90M with the revenue now reading -0.63 cents per share. This is a figure that is close to analyst’s prediction for their fourth quarter (0.41 cents a share).
Having a look at the company’s valuation, the company is expected to record 2.45 total earnings per share during the next fiscal year. It is very important though to remember that the importance of trend far outweighs that of outlook. This analysis has been great and getting further updates on XRAY sounds very interesting.
Is the stock of XRAY attractive?
In related news, Director, ALFANO MICHAEL C sold 2,500 shares of the company’s stock in a transaction that recorded on May 29. The sale was performed at an average price of 46.27, for a total value of 115,675. As the sale deal closes, the Director, BRANDT ERIC now sold 8,900 shares of the company’s stock, valued at 351,283. Also, Director, ALFANO MICHAEL C sold 10,665 shares of the company’s stock in a deal that was recorded on Nov 12. The shares were price at an average price of 56.27 per share, with a total market value of 600,110. Following this completion of acquisition, the Sr VP & Chief HR Officer, MacInnis Maureen J. now holds 15,000 shares of the company’s stock, valued at 840,900. In the last 6 months, insiders have changed their ownership in shares of company stock by 0.40%.
7 out of 16 analysts covering the stock have rated it a Buy, while 7 have maintained a Hold recommendation on DENTSPLY SIRONA Inc.. 0 analysts has assigned a Sell rating on the XRAY stock. The 12-month mean consensus price target for the company’s shares has been set at $49.33.